AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Allergan
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Healthy Adult Volunteers who have provided written informed consent

Exclusion Criteria:

• Volunteers with a history of upper gastrointestinal disease or who have a current diagnosis of upper gastrointestinal disease.

• Female volunteers who pregnant, nursing, or planning a pregnancy

• Volunteers with a history of drug or alcohol abuse